Table 2. Dual PI3K-mTOR, mTORC1 and mTORC2 inhibitors and status of drug development.
Phosphatydilinositol-3-kinase (PI3K); mammalian target of rapamycin (mTOR); mTOR complex (mTORC). Clinical Development, CD.
| Compound | Drug Company | Targets | Status |
|---|---|---|---|
| NVP-BGT226 | Novartis | PI3K/mTORC1/mTORC2 | CD terminated |
| NVP-BEZ235 | Novartis | PI3K/mTORC1/mTORC2 | Phase I/II |
| SF-1126 | Semaphore Pharmaceuticals | PI3K/mTORC1/mTORC2 | Phase I |
| XL-765 | Exelisis | PI3K/mTORC1/mTORC2 | Phase I/II |
| PKI-587/PF-05212384 | Pfizer | PI3K/mTOR | Phase I |
| PF-04691502 | Pfizer | PI3K/mTOR | Phase I |
| GDC-0980 | Genentech | PI3K/mTOR | Phase I |
| SB-2312 | S*Bio | PI3K/mTOR | Preclinical |
| PKI-402 | Pfizer | PI3K/mTOR | Preclinical |
| OSI-027 | Osi Pharmaceuticals | mTORC1/mTORC2 | Phase I |
| AZD-8055 | Astra Zeneca | mTORC1/mTORC2 | Phase I |
| INK-128 | Intellikine | mTORC1/mTORC2 | Phase I |
| XL-388 | Exelixis | mTORC1/mTORC2 | Preclinical |
| PP-242 | University of California | mTORC1/mTORC2 | Preclinical |
| PP-30 | University of California | mTORC1/mTORC2 | Preclinical |
| Torin-1 | Gray Laboratory Harvard | mTORC1/mTORC2 | Preclinical |
| KU-0063794 | Kudos Pharmaceuticals | mTORC1/mTORC2 | Preclinical |
| WYE-125132 | Wyeth | mTORC1/mTORC2 | Preclinical |
| Palomid-529 | Paloma Pharmaceuticals | mTORC1/mTORC2 | Preclinical |
| WAY-600 | Wyeth | mTORC1/mTORC2 | Preclinical |
| WYE-687 | Wyeth | mTORC1/mTORC2 | Preclinical |
| WYE-354 | Wyeth | mTORC1/mTORC2 | Preclinical |